Lb Pharmaceuticals (LBRX) Return on Capital Employed (2025 - 2026)
Lb Pharmaceuticals' (LBRX) quarterly Return on Capital Employed came in at 4.13% in Q1 2026, up 48.02% quarter-over-quarter from 7.94% in Q4 2025.
Lb Pharmaceuticals (LBRX) Return on Capital Employed (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 4.13% for Q1 2026.
- On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 4.13% in Q1 2026; TTM through Mar 2026 was 4.13%, a N/A change from a year earlier, with the FY2025 full-year figure at 2.69%, changed N/A from the prior year.
- Return on Capital Employed improved to 4.13% in Q1 2026 per LBRX's latest filing, from 7.94% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4.13% in Q1 2026 and bottomed at 7.94% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Lb Pharmaceuticals | 977.73 Mn | 977.73 Mn | - | -4.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.13% |
| Dec 31, 2025 | -7.94% |